UK: NICE Hints At ’Significant Changes’ To Come
Executive Summary
At a recent event in London, NICE, the health technology appraisal institute for England and Wales, hinted that it could be in for some big changes over the coming years.
You may also be interested in...
Competition Law Could Be Key To Lower Prices For Combo Drugs In UK
HTA body NICE is exploring whether competition law impacts pricing of combination drugs in UK.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.